In Reply: We agree with Drs Sarani and Gracias that the concerning results from the HBOC trials should not deter future research on technologies to minimize or avoid allogeneic transfusion. We also agree with Dr Sauaia and colleagues that there may be additional circumstances such as emerging pathogens and national emergencies that threaten the adequacy or quality of the US blood supply. However, it is important to assess the clinical consequences of each threat or harm with robust and ethical methodology.
Fergusson D, McIntyre L. Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply. JAMA. 2008;300(11):1295-1299. doi:10.1001/jama.300.11.1299